[ad_1]
Sundry Photography/iStock Editorial by way of Getty Images
Johnson & Johnson (NYSE:JNJ) continued gains for an eighth straight session, because the inventory closed 1.08% larger at $164.10 on Friday.
The New-Jersey primarily based healthcare big gained 2.44% within the previous seven sessions. Overall the inventory has gained about 3.6% up to now this yr in comparison with a 17% rise within the broader S&P 500 Index.
JNJ is up 2% over the previous one month. The inventory closed 0.57% larger on Thursday at $162.35.
Looking at Seeking Alpha’s Quant ranking, JNJ has a HOLD ranking with a rating of three.26 out of 5. The firm has acquired A+ by way of profitability, whereas an F within the prospect of revisions.
Among the Wall Street analysts, 11 analysts have given JNJ a Buy and above. 12 analysts suggest to Hold the inventory, whereas none of them suggest Sell.
Seeking Alpha analysts are additionally bullish and have rated the pharmaceutical big a Buy.
Johnson & Johnson’s chemotherapy-free drug mixture received approval within the U.S. on Tuesday because the first-line of remedy for sufferers with EGFR-mutated superior lung most cancers pointing in the direction of regained optimism within the inventory’s future.
JNJ additionally just lately introduced plans to amass V-Wave, an organization which focuses on remedy choices for cardiovascular ailments for an upfront fee of $600M.
Seeking Alpha investor Leo Nelissen was bullish on JNJ and famous that the corporate is regaining momentum with robust development in its MedTech section, pushed by new merchandise and strategic acquisitions.
More on Johnson & Johnson
[ad_2]
Source: Seekingalpha